A 3-Year Overall Survival Update From a Phase 2 Study of Chemoselection With DCF and Subsequent Conversion Surgery for Locally Advanced Unresectable Esophageal Cancer
| Autor: | Ken Kato, Shuichi Hironaka, Takashi Kojima, Hiroki Hara, Hisayuki Matsushita, Yuko Kitagawa, Yoshinori Ito, Takayuki Kii, Yasuo Hamamoto, Keisho Chin, Yasuhiro Tsubosa, Rie Nagumo, Hirofumi Ogawa, Yasushi Kojima, Kentaro Kawakami, Takashi Makiuchi, Yasunori Akutsu, Tomoya Yokota, Keita Mori, Takashi Ura |
|---|---|
| Rok vydání: | 2019 |
| Předmět: |
Male
medicine.medical_specialty Esophageal Neoplasms Phases of clinical research Docetaxel Metastasis 03 medical and health sciences 0302 clinical medicine Surgical oncology Antineoplastic Combined Chemotherapy Protocols medicine Humans Aged business.industry Induction chemotherapy Cancer Chemoradiotherapy Induction Chemotherapy Middle Aged Esophageal cancer Prognosis medicine.disease Surgery Supraclavicular lymph nodes Esophagectomy Survival Rate medicine.anatomical_structure Oncology 030220 oncology & carcinogenesis Female 030211 gastroenterology & hepatology Esophageal Squamous Cell Carcinoma Fluorouracil Cisplatin Neoplasm Recurrence Local business Follow-Up Studies medicine.drug |
| Zdroj: | Annals of Surgical Oncology. 27:460-467 |
| ISSN: | 1534-4681 1068-9265 |
| Popis: | A multicenter phase 2 trial analysed chemoselection with docetaxel plus 5-fluorouracil and cisplatin (DCF) induction chemotherapy (ICT) and subsequent conversion surgery (CS) for locally advanced unresectable esophageal cancer. This study presents updated 3-year analyses to further characterize the impact of DCF-ICT followed by CS. Esophageal cancer patients with clinical T4 disease, unresectable supraclavicular lymph node metastasis, or both were eligible for this study. The treatment starts with DCF-ICT, followed by CS if the cancer is resectable, or by concurrent chemoradiation if it is not resectable. This updated analysis presents 3-year overall survival (OS), 3-year progression-free survival (PFS), and pattern of relapse. The median follow-up period for the patients surviving without death was 39.3 months. The estimated 1-year OS was 66.7%, and the lower limit of the 80% confidence interval (CI) was 54.6%. The estimated 3-year OS was 46.6% (95% CI 34.2–63.5%). The OS for the patients who underwent R0 resection (n = 19) was significantly longer than for those who did not (3-year OS: 71.4% vs. 30.1%). The estimated 1-year PFS was 50.6%, and the 3-year PFS was 39.6%. The PFS for R0 was significantly longer than for non-R0 (3-year PFS: 61.3% vs 25.0%). Recurrence or progression at the primary site was observed in 31% of the non-R0 group. The rate of distant metastasis did not differ significantly between the non-R0 and R0 groups (21% vs 16%). Long-term follow-up evaluation confirmed that DCF chemoselection aimed at CS is feasible and promising in terms of survival for patients with locally advanced esophageal cancer. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Full text from SpringerLink